Last mentioned: Mar 19, 2026
Runway Horizon
Current capital projected to fund operations through significant commercial milestones.
Cash Runway Limit
Current capital projected to fund operations through this period across commercial milestones.
2026 Target
Goal to reach 15-17 states and operate 5-7 live partner programs.
Commercial Target
Goal to reach 15-17 states and 5-7 live partner programs.
Q4 Earnings Call
Management outlines pivot from R&D to commercial scaling and state-level engagement.
Q4 Earnings Call
Management confirms runway through 2028 and details PRIME study impact.
Sera Prognostics Commercial Pivot
Announces target to reach 15-17 states and 60% of US births by year-end.
Meta-Oklo Agreement
Execution of 1.2GW Aurora power campus development in Ohio.
Ecopetrol Dividend Proposal
Board proposes COP 110 per share dividend representing 50% of net income.
Oklo Capital Raise
Raises $1.182 billion net through ATM program to fund Aurora projects.
Fiscal Year End
Sera concludes 2025 with $95.8M cash and successful PRIME study publication.
Fiscal Year End
Sera concludes 2025 with $95.8M in cash and a narrowed net loss.
Ecopetrol Production Peak
Reports highest production in a decade at 751,000 boe/d.
The Q4 2025 earnings cycle highlights a critical shift for growth-stage public companies, where massive capital reserves and operational efficiency are being prioritized over immediate revenue. From Oklo's multi-billion dollar infrastructure plays to Sera Prognostics' clinical-milestone focus, the 'Strategic Endurance' model is now the primary driver of market sentiment.
The Q4 2025 earnings cycle reveals a stark divergence between high-growth infrastructure bets and established retail and energy players navigating macroeconomic headwinds. While nuclear energy and biotech firms are securing massive capital for long-term deployments, consumer-facing giants like lululemon are grappling with regional stagnation and tariff-driven margin compression.
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. The company is pivoting toward large-scale commercialization of its PreTRM test following landmark PRIME study data showing a 56% reduction in very early preterm births.
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. Following the successful publication of its PRIME study—which demonstrated a 56% reduction in very preterm births—the company is aggressively shifting its focus toward state-level payer engagement and commercial scaling.